ICON
today announced its ongoing expansion in Asia-Pacific. ICON has opened a new office in Shanghai, China, and is also relocating its Beijing operations to larger premises. In addition, ICON has announced the appointment Dr. Malcolm Burgess, to the position of Executive Vice President, Asia-Pacific, and Ms. Paula Mumby, Vice President, Operations, Asia-Pacific for ICON’s resourcing business unit, DOCS.
Dr. Malcolm Burgess joined ICON in 2002 and has held a variety of leadership positions within the company, including Chief Operating Officer, US Operations from 2006 – 2009. He has over 30 years’ experience within the pharmaceutical industry and prior to ICON worked with Novartis, Hoechst Marion Roussel and SmithKline Beecham.
Ms. Paula Mumby has over 18 years’ experience in the pharmaceutical, CRO, biotechnology and medical device industries in the UK and Asia Pacific and has more than 10 years’ resourcing experience. Prior to joining DOCS, Ms. Mumby was Vice President, Asia Pacific and Japan at i3 Pharma Resourcing and also held a clinical development role at CSL.
ICON has been operating in Asia-Pacific for over 10 years and currently employs over 900 staff in the region. The new office in Shanghai follows ICON’s announcement in June 2010 of a new laboratory facility, which opened in Tianjin, China, in partnership with Fountain Medical Development Ltd (FMD). The new laboratory is ICON’s third laboratory in Asia-Pacific, and offers 3,000 square feet of laboratory space and a comprehensive menu of testing services.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.